Zepbound
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Zepbound in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Zepbound.
2
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Zepbound
The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels
Approximately 38.4 million people in the US are affected by diabetes
The deal gives Lilly exclusive global rights to incretin products based on Camurus’ technology
Patients treated with Lilly’s drug achieved an average weight reduction of 20.2%
The investment will provide an additional 200 jobs and more than 5,000 construction jobs during development of the site
The drug has been authorised for use alongside a reduced-calorie diet and physical activity
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology